# Artificial Intelligence in Pathology

> Artificial intelligence in pathology for NEET-PG: digital slide analysis, screening algorithms and validation limits in one line each.

- Canonical URL: https://prepelephant.com/topics/neet-pg/pathology/artificial-intelligence-pathology
- Exam / course: NEET-PG · Subject: Pathology
- Publisher: PrepElephant (https://prepelephant.com) — Prepared and reviewed by the PrepElephant Academic Review Team
- First published: 2026-10-02
- Last updated: 2026-10-02
- How to cite: "Artificial Intelligence in Pathology", PrepElephant, https://prepelephant.com/topics/neet-pg/pathology/artificial-intelligence-pathology

## Direct answer

Artificial intelligence in pathology means deep-learning software that reads digitised whole-slide images and performs a defined task, such as flagging suspicious prostate biopsy regions, detecting nodal metastases or counting mitoses, while the pathologist remains responsible for the report. The landmark demonstrations are CAMELYON16 (2017), where the best of 32 algorithms matched a panel of 11 pathologists for breast lymph-node metastasis detection, and the PANDA challenge, where top Gleason-grading algorithms agreed with expert uropathologists more closely than general pathologists did. Regulatory reality is narrower: only a handful of tools are cleared, each for one indication, and validation on local material is mandatory before deployment.

## What you must remember

- **Substrate, the digital slide:** AI runs only on whole-slide images; vendor formats (SVS, NDPI, MRXS, SCN) coexist with the DICOM whole-slide imaging standard, and a poor scan defeats it before it starts.
- **CAMELYON16 (JAMA 2017):** 32 deep-learning algorithms for breast nodal metastasis detection; the best slide-level AUC was 0.994 against a mean of 0.966 for the 11 participating pathologists.
- **PANDA (Nature Medicine 2022):** for Gleason grading of prostate needle biopsies, the top algorithms reached a quadratic weighted kappa of about 0.87 against the expert reference; general pathologists scored about 0.78.
- **First clearances:** Paige Prostate (FDA De Novo, 2021, first AI software cleared for pathology) flags suspicious regions in prostate core biopsies; Europe has CE-marked detection modules and, since 2025, the first cleared AI mitosis tool.
- **Mitosis counting:** in the MITOS-ATYPIA-14 breast-cancer benchmark, the best algorithms matched the average pathologist, removing the interobserver variability that clouds Nottingham grade 2 tumours.
- **Validation:** independent, institution-representative test cases with pre-specified metrics under the College of American Pathologists machine-learning framework; a new scanner, stain or population reopens the validation question.
- **Limitations:** domain shift across scanners and laboratories, under-represented rare subtypes, and artefacts such as folds, bubbles, ink and blur misread as disease; many outputs carry no histological explanation.
- **Accountability:** locked algorithms are regulated as medical devices (FDA, EU in-vitro diagnostic rules, India's Medical Devices Rules 2017), and the pathologist owns the final diagnosis.

## How an algorithm earns a place on the bench

An approved algorithm still has to earn trust locally, and the pathway is standard. First, intended use: a tool cleared to flag suspicious regions in prostate core biopsies is not cleared for cytology, breast or resection specimens, and use beyond scope is unregulated improvisation. Second, the institution tests the locked algorithm (weights frozen, no retraining) on its own consecutive cases spanning the diagnostic spectrum: benign mimics, atypical glands, post-radiotherapy change, every scanner and stain in service. Metrics are pre-specified: sensitivity at a tolerated false-positive rate per slide for detection tasks, quadratic weighted kappa for grading. Third comes prospective shadow-mode running, where the algorithm works alongside routine sign-out and every disagreement is adjudicated. Once deployed, surveillance never stops: periodic re-audit against glass-slide diagnoses and drift checks after scanner servicing or a new stain batch. In the cleared prostate workflow the software pre-screens the slide, and the pathologist reviews flagged regions plus a sample of unflagged tissue; the human, not the machine, remains accountable for the report.

## How the exam frames it, and what Indian laboratories face

At DM histopathology viva level, the question is rarely "what is deep learning"; it is a scenario: a vendor offers a Gleason-grading algorithm to your centre, what will you check before use. The marks sit in the structure: intended use, validation dataset, agreement statistics, artefact behaviour, medico-legal accountability. The examiner's trap is the extreme response; claiming the algorithm will replace pathologists and dismissing it as a research toy both signal a candidate who has not followed the literature. The Indian laboratory adds a second layer: most diagnostic histopathology in the country is still reported from glass slides, scanning capacity clusters in large cancer centres and corporate chains, and cleared AI tools are priced for Western workflows, so deployment debates turn on cost per case and accreditation scope. ICMR's ethical guidance on artificial intelligence in healthcare (2023) supplies the national framing of human oversight, data protection and bias monitoring, and examiners increasingly expect candidates to cite it.

## Frequently asked questions

### Which was the first FDA-cleared AI software in pathology?

Paige Prostate, authorised through the De Novo pathway in 2021, flags regions suspicious for cancer in prostate core needle biopsies.

### How closely do algorithms match expert Gleason grading?

In the PANDA challenge the best algorithms reached a quadratic weighted kappa of about 0.87 against the expert reference; general pathologists scored about 0.78.

### What is domain shift in computational pathology?

Performance drops when the scanner, stain or patient population differs from the training data, which is why every laboratory validates the tool on its own material before use.

### Does an AI tool take over the sign-out?

No, cleared tools are assistive; the pathologist reviews the output and remains legally responsible for the final diagnosis.

### Which artefacts mislead image-analysis algorithms?

Tissue folds, air bubbles, marker-pen ink, blur and out-of-focus tiles can be misread as pathology, so digitisation quality control is part of AI safety.